Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $34.11
Previous CloseN/A
Volume216.17K
Average Volume (3M)2.01M
Market Cap
$556.92M
Enterprise Value$1.74B
Total Cash (Recent Filing)$954.30M
Total Debt (Recent Filing)$10.50M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 31, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding72,991,390
10 Day Avg. Volume1,917,858
30 Day Avg. Volume2,008,086
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.22
Price to Sales (P/S)0.00
P/FCF Ratio-6.49
Enterprise Value/Market Cap3.13
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit4.12
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$14.53Price Target Upside90.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas Elects New Directors and Ratifies Auditor
PremiumCompany Announcements
Arvinas Unveils Promising ARV-393 Data at EHA Congress
PremiumCompany Announcements
Arvinas R&D President Ian Taylor Resigns
PremiumCompany Announcements
Arvinas and Pfizer Submit New Drug Application
Bulls Say, Bears Say
Bulls Say
Drug EfficacyVepdeg is viewed as a potential best-in-class 2L treatment for ESR1m mBC patients with a 2.9-month PFS benefit, demonstrating improved efficacy without compromising safety or tolerability.
Market PositioningPfizer's strong presence in breast cancer is expected to help drive the adoption of vepdegestrant.
Bears Say
Market CompetitionThe emergence of new data suggests a shift in treatment standards, which could limit the addressable market for Arvinas' lead drug.
Partnership UncertaintyThere is expected volatility in ARVN shares as discussions continue regarding the future of the Pfizer partnership.
Ownership Overview
2.53% Insiders
23.20% Mutual Funds
34.96% Other Institutional Investors
24.71% Public Companies and Individual Investors
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $34.11 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $556.92M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Jul 31, 2025 which is in 28 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 01, 2025. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of -$0.965 by $2.105.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.94.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 72,991,390 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $1.14 in its last earnings report, beating expectations of -$0.965. Following the earnings report the stock price went down -24.844%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.53 (90.43% Upside)
$14.53 (90.43% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $62.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.63%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-17.44%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas Holding Company (ARVN) is a biopharmaceutical company engaged in the research and development of therapeutics aimed at degrading disease-causing proteins. The company operates in the healthcare sector, focusing on creating innovative protein degradation therapies for the treatment of cancers and other serious diseases. Arvinas leverages its proprietary PROTAC (PROteolysis TArgeting Chimeras) technology platform to develop small molecule therapies that harness the body's natural protein disposal system to selectively degrade and eliminate unwanted proteins.
ARVN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant progress in clinical trials, especially for Vepdegestrant and ARV-102. However, the removal of planned phase 3 trials and workforce reductions indicate challenges and strategic realignments.Read More>ARVN Stock 12 Month Forecast
Average Price Target
$14.53
▲(90.43%Upside)